Manning M, Nawrocka E, Misicka A, Olma A, Klis W A, Seto J, Sawyer W H
J Med Chem. 1984 Apr;27(4):423-9. doi: 10.1021/jm00370a002.
As part of a program in which we are attempting (a) to obtain more potent and/or more selective antagonists of the antidiuretic responses to arginine-vasopressin (AVP) and (b) to delineate the structural features at positions 1-9 required for antidiuretic antagonism, we have synthesized 13 new analogues of the antidiuretic antagonist [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin [d(CH2)5[D-Ile2]VAVP] in which the valine residue at position 4 has been replaced by the L-amino acids Abu, Ile, Thr, Ala, Ser, Nva, Gln, Leu, Lys, Cha, Asn, Orn, and Phe and two new analogues of the antidiuretic antagonist [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-phenylalanine,4- valine]arginine-vasopressin [d(CH2)5[D-Phe2]VAVP] with the Val4 residue replaced by Ser and Orn. These analogues are 1, d(CH2)5[D-Ile2,Abu4]AVP; 2, d(CH2)5[D-Ile2,Ile4]AVP; 3, d(CH2)5[D-Ile2,Thr4]AVP; 4, d(CH2)5[D-Ile2,Ala4]AVP; 5, d(CH2)5[D-Ile2,Ser4]AVP; 6, d(CH2)5[D-Ile2,Nva4]AVP; 7, d(CH2)5[D-Ile2]AVP; 8, d(CH2)5[D-Ile2,Leu4]AVP; 9, d(CH2)5[D-Ile2,Lys4]AVP; 10, d(CH2)5[D-Ile2,Cha4]AVP; 11, d(CH2)5[D-Ile2,Asn4]AVP; 12, d(CH2)5[D-Ile2,Orn4]AVP; 13, d(CH2)5[D-Ile2,Phe4]AVP; 14, d(CH2)5[D-Phe2,Ser4]AVP; and 15, d(CH2)5[D-Phe2,Orn4]AVP. The protected peptide precursors for these peptides were prepared by the solid-phase method, followed by ammonolytic cleavage. The free peptides 1-15 were obtained by deblocking with Na in NH3, oxidation of the resultant disulfhydryl compounds with dilute K3[Fe(CN)6], and purification on Sephadex G-15 in a two-step procedure with 50% HOAc and 0.2 M HOAc as eluants. Analogues 1-15 were tested in rats for agonistic and antagonistic activities by antidiuretic, vasopressor, and oxytocic assays.(ABSTRACT TRUNCATED AT 250 WORDS)
作为我们正在进行的一项研究计划的一部分,该计划旨在(a)获得对精氨酸加压素(AVP)抗利尿反应更有效和/或更具选择性的拮抗剂,以及(b)确定抗利尿拮抗作用所需的1 - 9位的结构特征,我们合成了13种抗利尿拮抗剂[1 - (β - 巯基 - β,β - 五亚甲基丙酸),2 - D - 异亮氨酸,4 - 缬氨酸]精氨酸加压素[d(CH2)5[D - Ile2]VAVP]的新类似物,其中4位的缬氨酸残基已被L - 氨基酸Abu、Ile、Thr、Ala、Ser、Nva、Gln、Leu、Lys、Cha、Asn、Orn和Phe取代,以及两种抗利尿拮抗剂[1 - (β - 巯基 - β,β - 五亚甲基丙酸),2 - D - 苯丙氨酸,4 - 缬氨酸]精氨酸加压素[d(CH2)5[D - Phe2]VAVP]的新类似物,其Val4残基被Ser和Orn取代。这些类似物分别是:1,d(CH2)5[D - Ile2,Abu4]AVP;2,d(CH2)5[D - Ile2,Ile4]AVP;3,d(CH2)5[D - Ile2,Thr4]AVP;4,d(CH2)5[D - Ile2,Ala4]AVP;5,d(CH2)5[D - Ile2,Ser4]AVP;6,d(CH2)5[D - Ile2,Nva4]AVP;7,d(CH2)5[D - Ile2]AVP;8,d(CH2)5[D - Ile2,Leu4]AVP;9,d(CH2)5[D - Ile2,Lys4]AVP;10,d(CH2)5[D - Ile2,Cha4]AVP;11,d(CH2)5[D - Ile2,Asn4]AVP;12,d(CH2)5[D - Ile2,Orn4]AVP;13,d(CH2)5[D - Ile2,Phe4]AVP;14,d(CH2)5[D - Phe2,Ser4]AVP;以及15,d(CH2)5[D - Phe2,Orn4]AVP。这些肽的保护肽前体通过固相法制备,随后进行氨解裂解。游离肽1 - 15通过在液氨中用钠脱保护、用稀K3[Fe(CN)6]氧化所得的二硫化合物,并在Sephadex G - 15上以50%乙酸和0.2 M乙酸作为洗脱剂分两步进行纯化而获得。通过抗利尿、升压和催产素测定法在大鼠中测试类似物1 - 15的激动和拮抗活性。(摘要截短于250字)